Paper30765477
SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA.
Nimmagadda SC and 7 others. Haematologica, 2019. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA. Papers, record 30765477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30765477
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Agammaglobulinaemia Tyrosine Kinase | Major topic |
| Chemokine CXCL12 | Major topic |
| Chemotaxis | Major topic |
| Gene Expression Regulation | Major topic |
| Janus Kinase 2 | Major topic |
| Mutation | Major topic |
| Myeloid Progenitor Cells | Major topic |
| Cell Movement | |
| Cells, Cultured | |
| Humans | |
| Phosphatidylinositol 3-Kinases | |
| Phospholipase C gamma | |
| Proto-Oncogene Proteins c-akt | |
| rhoA GTP-Binding Protein |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22160036 | Genetic and epigenetic complexity in myeloproliferative neoplasms. | Hematology Am Soc Hematol Educ Program | 2011 | https://conductscience.org/library/papers/22160036 | PubMed |
| 2 | 20843246 | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20843246 | PubMed |
| 3 | 28536953 | RhoA and RhoC are involved in stromal cell-derived factor-1-induced cell migration by regulating F-actin redistribution and assembly. | Mol Cell Biochem | 2017 | https://conductscience.org/library/papers/28536953 | PubMed |
| 4 | 9755164 | Tec/Bmx non-receptor tyrosine kinases are involved in regulation of Rho and serum response factor by Galpha12/13. | EMBO J | 1998 | https://conductscience.org/library/papers/9755164 | PubMed |
| 5 | 21321325 | Rho GTPases and their role in organizing the actin cytoskeleton. | J Cell Sci | 2011 | https://conductscience.org/library/papers/21321325 | PubMed |
| 6 | 17239630 | Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. | Immunity | 2007 | https://conductscience.org/library/papers/17239630 | PubMed |
| 7 | 25394487 | Epo-induced erythroid maturation is dependent on Plcγ1 signaling. | Cell Death Differ | 2015 | https://conductscience.org/library/papers/25394487 | PubMed |
| 8 | 24307721 | Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. | Blood | 2014 | https://conductscience.org/library/papers/24307721 | PubMed |
| 9 | 18292289 | Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. | Blood | 2008 | https://conductscience.org/library/papers/18292289 | PubMed |
| 10 | 25461253 | C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. | Exp Hematol | 2015 | https://conductscience.org/library/papers/25461253 | PubMed |
| 11 | 29109446 | Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia. | Leukemia | 2018 | https://conductscience.org/library/papers/29109446 | PubMed |
| 12 | 28233092 | Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. | J Cancer Res Clin Oncol | 2017 | https://conductscience.org/library/papers/28233092 | PubMed |
| 13 | 25565020 | Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma. | Cell Cycle | 2015 | https://conductscience.org/library/papers/25565020 | PubMed |
| 14 | 29121538 | Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms. | Leuk Res | 2017 | https://conductscience.org/library/papers/29121538 | PubMed |
| 15 | 25294819 | Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. | Oncotarget | 2014 | https://conductscience.org/library/papers/25294819 | PubMed |
| 16 | 28903325 | CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. | Oncotarget | 2017 | https://conductscience.org/library/papers/28903325 | PubMed |
| 17 | 26538820 | Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. | Mediators Inflamm | 2015 | https://conductscience.org/library/papers/26538820 | PubMed |
| 18 | 28314843 | Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status. | Mol Cancer Res | 2017 | https://conductscience.org/library/papers/28314843 | PubMed |
| 19 | 30024857 | JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. | J Clin Invest | 2018 | https://conductscience.org/library/papers/30024857 | PubMed |
| 20 | 27376361 | Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. | Ann Hematol | 2016 | https://conductscience.org/library/papers/27376361 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35205715 | Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35205715 | PubMed |
| 34592754 | Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F-induced disease. | Blood Adv | 2021 | https://conductscience.org/library/papers/34592754 | PubMed |
| 33641869 | Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology. | Hematol Oncol Clin North Am | 2021 | https://conductscience.org/library/papers/33641869 | PubMed |
| 32112045 | Bone marrow niches in haematological malignancies. | Nat Rev Cancer | 2020 | https://conductscience.org/library/papers/32112045 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| BTK | 695 | PubTator's text mining | https://conductscience.org/library/genes/695 | NCBI Gene |
| JAK2 | 3717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
| PLCG1 | 5335 | PubTator's text mining | https://conductscience.org/library/genes/5335 | NCBI Gene |
| RHOA | 387 | PubTator's text mining | https://conductscience.org/library/genes/387 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30765477
GET https://conductscience.org/api/papers/v1/30765477/references?page=2